Results 171 to 180 of about 20,878 (216)

Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study. [PDF]

Front Oncol
Ivanovic J, Otasevic V, Markovic K, Vukovic V, Bibic T, Tomic Vujovic K, Kozarac S, Vladicic Masic J, Milic N, Kulic J, Antic D.   +10 more
europepmc   +1 more source

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study. [PDF]

Biomedicines
Font J, Hodzic A, Da-Silva A, Delapierre B, Damaj G, Neusy A, Plane AF, Legallois D, Milliez P, Dolladille C, Vernon M, Burton S, Vigneron N, Denoyelle C, Alexandre J.   +14 more
europepmc   +1 more source

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE. [PDF]

Ann Hematol
Mishima Y, Hashimoto D, Ichii M, Fukuhara N, Uchida T, Kato K, Omi A, Koroki Y, Shiga K, Maruyama D.   +9 more
europepmc   +1 more source

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment. [PDF]

BMC Cancer
Herold S, Schmidt C, Visco C, Tilch MK, Ohler A, Unterhalt M, Hoster E, Hoenig E, Singer S, Tucci A, Pott C, Ladetto M, Hess G, Dreyling M.   +13 more
europepmc   +1 more source

Inhibition of BTK and SYK attenuates <i>Porphyromonas gingivalis</i> -induced activation of the pyroptosis pathway and inflammation in host cells. [PDF]

J Oral Microbiol
Plonczynska A, Schuster A, Drapala DM, Kaczmarzyk T, Nowak M, Potempa J, Grabiec AM, Sochalska M.   +7 more
europepmc   +1 more source

Data from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

Beatriz Rey-Búa, Carlos Grande, José Javier Sánchez Blanco, Pau Abrisqueta, Antonio Gutiérrez, Ángel Ramírez Páyer, Eva Giné, Izaskun Zeberio, María José Terol, Fátima de la Cruz Vicente, Rafel Andreu, M.J. Ramírez, Adolfo de la Fuente, María C. Viguria, María Jesús Peñarrubia, Ana Jiménez‐Ubieto, Santiago Montes‐Moreno, Armando López‐Guillermo, M. D. Caballero, Alejandro Martı́n   +19 more
openalex   +1 more source

A Durable Remission Following Pseudo-Progression in Tirabrutinib Treatment for Relapsed Primary Central Nervous System Lymphoma: A Case Study. [PDF]

Case Rep Hematol
Okawara S, Ide S, Morimoto H, Tsukada J.
europepmc   +1 more source

Integrative green synthesis and molecular simulation of ibrutinib cocrystals for enhanced biopharmaceutical performance and in vivo pharmacokinetics. [PDF]

Int J Pharm X
Kara DD, Bangera PD, Keerikkadu M, Rathnanand M.   +3 more
europepmc   +1 more source

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]

Blood Res
Hur JY, Lee JH, Lee JH, Park HS, Park H, Choi Y, Choi JH, Won YW, Yoon SE, Kim WS, Kim SJ.   +10 more
europepmc   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source